-
1.发明申请COMPOSITIONS AND METHODS FOR THE TREATMENT OR PREVENTION OF OXALATE-RELATED DISORDERS 审中-公开用于治疗或预防与草酸相关的病症的组合物和方法
公开(公告)号：WO2017216165A1
公开(公告)日：2017-12-21
申请号：PCT/EP2017/064422
申请日：2017-06-13
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , ÅKERMAN, Maria , SJÖGREN, Anna , MCCALLION, Orla
CPC classification number: A61K35/74 , A61K9/4866 , A61K9/4891 , A61P1/00
Abstract: The present disclosure is related to pharmaceutical compositions and methods for treating and/or preventing oxalate-related disorders. More particularly, the present disclosure pertains to compositions comprising an oxalate- degrading bacteria Oxalobacter formigenes particularly suitable for the treatment and/or prevention of late stage hyperoxaluria characterized by high plasma-oxalate levels and a progressing decrease in kidney function.
Abstract translation: 本公开涉及用于治疗和/或预防草酸盐相关病症的药物组合物和方法。 更具体地说，本公开涉及包含特别适用于治疗和/或预防晚期高草酸盐特征的草酸盐降解菌草酸甲酸甲酯的组合物，所述草酸盐降解菌特别适用于治疗和/或预防高血浆草酸盐水平和肾脏进行性降低 功能
-
公开(公告)号：WO2015002604A1
公开(公告)日：2015-01-08
申请号：PCT/SE2014/050848
申请日：2014-07-03
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , COWLEY, Helena , COWLEY, Aaron
CPC classification number: C07K14/195 , A61K35/74 , A61K38/00 , A61K38/164 , C12N9/0006 , C12N9/0016 , C12N9/0051 , C12N9/1014 , C12N9/1085 , C12N9/14 , C12N9/88 , C12Y101/0106 , C12Y104/01016 , C12Y108/01 , C12Y201/02001 , C12Y205/01006 , C12Y205/01009 , C12Y205/01047 , C12Y303/01001 , C12Y402/01003
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Abstract translation: 本发明涉及一种衍生自草酸降解细菌的促分泌素化合物，用于治疗受试者中草酸盐相关疾病和/或草酸盐相关的不平衡，其中所述促分泌素的施用导致尿草酸盐和/或 受试者血浆草酸盐。 本发明还涉及包含这种促分泌素化合物的药物组合物，用于治疗患有草酸盐相关疾病的受试者的方法和一种制备促分泌素的方法。
-
公开(公告)号：WO2020071994A1
公开(公告)日：2020-04-09
申请号：PCT/SE2019/050970
申请日：2019-10-04
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , DEHMEL, Bastian , ÅKERMAN, Maria
Abstract: The present invention relates to the treatment or prevention of oxalate-related disorders, more particularly to the use of a pharmaceutical composition comprising Oxalobacter formigenes in the treatment or prevention of systemic oxalosis with cardiac involvement.
-
Patent Agency Ranking
公开(公告)号：WO2015002588A1
公开(公告)日：2015-01-08
申请号：PCT/SE2013/050875
申请日：2013-07-05
Applicant: OXTHERA INTELLECTUAL PROPERTY AB
Inventor： LINDNER, Elisabeth , COWLEY, Helena , COWLEY, Aaron
CPC classification number: C07K14/195 , A61K35/74 , A61K38/00 , A61K38/164 , C12N9/0006 , C12N9/0016 , C12N9/0051 , C12N9/1014 , C12N9/1085 , C12N9/14 , C12N9/88 , C12Y101/0106 , C12Y104/01016 , C12Y108/01 , C12Y201/02001 , C12Y205/01006 , C12Y205/01009 , C12Y205/01047 , C12Y303/01001 , C12Y402/01003
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
Abstract translation: 本发明涉及用于治疗受试者中草酸盐相关疾病和/或草酸盐相关失衡的衍生自草酸盐降解菌的促分泌素化合物，其中所述促分泌素的施用导致 对象中尿草酸盐和/或草酸盐的减少。 本发明进一步涉及包含这种促分泌素化合物的药物组合物，治疗患有草酸盐相关疾病的对象的方法，以及制备促分泌素的方法。
-
公开(公告)号：EP3865148A1
公开(公告)日：2021-08-18
申请号：EP21165678.0
申请日：2014-07-03
Applicant: OxThera Intellectual Property AB
Inventor： LINDNER, Elisabeth , COWLEY, Helena , COWLEY, Aaron , ÅKERMAN, Maria
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
-
公开(公告)号：EP3860628A1
公开(公告)日：2021-08-11
申请号：EP19868730.3
申请日：2019-10-04
Applicant: OxThera Intellectual Property AB
Inventor： LINDNER, Elisabeth , DEHMEL, Bastian , ÅKERMAN, Maria
-
公开(公告)号：EP3468572A1
公开(公告)日：2019-04-17
申请号：EP17730457.3
申请日：2017-06-13
Applicant: OxThera Intellectual Property AB
Inventor： LINDNER, Elisabeth , ÅKERMAN, Maria , SJÖGREN, Anna , MCCALLION, Orla
-
公开(公告)号：EP3016669A1
公开(公告)日：2016-05-11
申请号：EP14747997.6
申请日：2014-07-03
Applicant: OxThera Intellectual Property AB
Inventor： LINDNER, Elisabeth , COWLEY, Helena , COWLEY, Aaron
CPC classification number: C07K14/195 , A61K35/74 , A61K38/00 , A61K38/164 , C12N9/0006 , C12N9/0016 , C12N9/0051 , C12N9/1014 , C12N9/1085 , C12N9/14 , C12N9/88 , C12Y101/0106 , C12Y104/01016 , C12Y108/01 , C12Y201/02001 , C12Y205/01006 , C12Y205/01009 , C12Y205/01047 , C12Y303/01001 , C12Y402/01003
Abstract: The present invention relates to a secretagogue compound derived from oxalate degrading bacteria, for use in the treatment of an oxalate related disease and/or oxalate related imbalance in a subject, wherein the administration of the secretagogue results in a reduction of urinary oxalate and/or plasma oxalate in the subject. The invention further relates to a pharmaceutical composition comprising such a secretagogue compound, a method for treating a subject suffering from an oxalate related disease, and to a method for preparing a secretagogue.
-
-
-
-
-
-
-
Search Results
8
records
(took 0.022 seconds)
